When IT professional Terry Pirovolakis received his son Michael’s diagnosis of hereditary spastic paraplegia 50 (SPG 50) in 2019, doctors offered no options. According to the Science History Institute, the ultra-rare genetic disease—affecting fewer than 100 people worldwide—causes severe cognitive and physical decline, and clinicians told the family that no treatments or clinical trials existed.
Reframing Technical Skills for Medicine
Rather than accepting the prognosis, Pirovolakis applied two decades of enterprise IT project management experience to medicine. He reasoned that managing large-scale global infrastructure projects required similar coordination: assembling specialized teams, securing capital, and driving timelines under immense pressure.
To fund the initiative, he refinanced his home and established a charity, raising millions of dollars through local fundraisers, galas, and public appeals. He approached gene therapy experts at academic conferences, securing a collaboration with Dr. Steven Gray to design a targeted treatment. To accelerate the typical five-to-seven-year timeline, Pirovolakis ran preclinical validation, safety studies, and manufacturing in parallel.
From a Single Trial to a Lifeline for Others
In March 2022, Michael received the custom gene therapy in a single-patient clinical trial at the University of Texas. The treatment successfully targeted the underlying genetic mutation, leading to noticeable improvements in his mobility and cognitive engagement.
Pirovolakis’s effort soon grew beyond his own household. When other parents, such as Rebekah and Evan Lockard, received the same devastating SPG 50 diagnosis for their daughter Naomi in 2023, his established foundation provided guidance and access to a treatment framework that had not previously existed.
Editorial Reflection
This parent-led effort illustrates how high-stakes problem-solving skills from technology can intersect with biomedical research. Because commercial drug development often bypasses ultra-rare conditions due to limited market size, persistent individuals sometimes step in to bridge critical gaps, demonstrating the unexpected ways technological engineering mindsets can reshape rare disease advocacy.
AI-generated editorial illustration; not a documentary photograph.
Source: Distillations podcast
Gene Therapy’s Families
SIGNAL TITANS
Leave a Reply